Carl Zeiss Meditec AG (MEX:AFXN) Cyclically Adjusted Revenue per Share: MXN1,735.81 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AFXN Carl Zeiss Meditec AG MEX:AFXN
81 GF Score
Price MXN3,258.20
GF Value MXN8,007.11
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share?

Carl Zeiss Meditec AG MEX:AFXN 81 Cyclically Adjusted Revenue per Share is MXN1,735.81 as of Dec. 2025. GuruFocus rates MEX:AFXN with a GF Score™ of 81/100 and a GF Value™ of MXN8,007.11. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Carl Zeiss Meditec AG's adjusted revenue per share for the three months ended in Dec. 2025 was MXN120.565. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN1,735.81 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Carl Zeiss Meditec AG's average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Carl Zeiss Meditec AG was 11.40% per year. The lowest was 5.30% per year. And the median was 8.65% per year.

As of today (2026-08-09), Carl Zeiss Meditec AG's current stock price is MXN3258.20. Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was MXN1,735.81. Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio of today is 1.88.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Carl Zeiss Meditec AG was 13.68. The lowest was 1.10. And the median was 6.23.


Carl Zeiss Meditec AG  (MEX:AFXN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3258.20/1735.81
=1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Carl Zeiss Meditec AG was 13.68. The lowest was 1.10. And the median was 6.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Related Terms


Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 353.12 509.73 728.98 904.42 1,634.51

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,435.84 1,098.43 1,186.67 1,634.51 1,735.81

MEX:AFXN vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carl Zeiss Meditec AG Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio falls into.


MEX:AFXN
81GF Score
Carl Zeiss Meditec AG MEX:AFXN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Carl Zeiss Meditec AG's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=120.565/129.3606*129.3606
=120.565

Current CPI (Dec. 2025) = 129.3606.

Carl Zeiss Meditec AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 65.260 100.017 84.407
201606 64.995 100.717 83.480
201609 78.428 101.017 100.434
201612 74.886 101.217 95.708
201703 75.780 101.417 96.660
201706 63.368 102.117 80.274
201709 78.093 102.717 98.349
201712 76.905 102.617 96.948
201803 80.333 102.917 100.974
201806 80.456 104.017 100.059
201809 85.324 104.718 105.403
201812 80.597 104.217 100.042
201903 84.549 104.217 104.947
201906 87.813 105.718 107.452
201909 104.325 106.018 127.295
201912 85.858 105.818 104.960
202003 99.821 105.718 122.145
202006 73.404 106.618 89.062
202009 108.491 105.818 132.629
202012 100.263 105.518 122.919
202103 108.909 107.518 131.034
202106 117.049 108.486 139.572
202109 120.813 109.435 142.811
202112 105.369 110.384 123.484
202203 108.685 113.968 123.364
202206 113.673 115.760 127.028
202209 126.506 118.818 137.731
202212 108.555 119.345 117.665
202303 108.289 122.402 114.445
202306 111.206 123.140 116.823
202309 121.166 124.195 126.206
202312 98.739 123.773 103.197
202403 95.289 125.038 98.583
202406 118.525 125.882 121.801
202409 145.228 126.198 148.868
202412 122.810 127.041 125.052
202503 142.080 127.779 143.838
202506 134.750 128.412 135.746
202509 154.943 129.255 155.069
202512 120.565 129.361 120.565

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN1,735.81 mean?
Carl Zeiss Meditec AG (MEX:AFXN) has a Cyclically Adjusted Revenue per Share of MXN1,735.81 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share too high?
Carl Zeiss Meditec AG's current Cyclically Adjusted Revenue per Share is MXN1,735.81. Overall, Carl Zeiss Meditec AG has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share of MXN1,735.81 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Cyclically Adjusted Revenue per Share is MXN1,735.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (MEX:AFXN) has a current Cyclically Adjusted Revenue per Share of MXN1,735.81. The stock's GF Value™ is MXN8,007.11, compared to a current price of MXN3,258.20 — trading 59.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN1,735.81. Carl Zeiss Meditec AG's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Carl Zeiss Meditec AG (MEX:AFXN), the current Cyclically Adjusted Revenue per Share is MXN1,735.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (MEX:AFXN) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of MXN3,258.20 is trading 59.3% below its estimated GF Value™ of MXN8,007.11.

Key valuation signals for MEX:AFXN:

  • Cyclically Adjusted Revenue per Share: MXN1,735.81
  • GF Value™: MXN8,007.11 vs. price of MXN3,258.20 (59.3% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the MEX:AFXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
81GF Score

Get the complete analysis for MEX:AFXN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,258.20
Price
MXN8,007.11
GF Value